European drug regulator allows Novo to include reduction of kidney disease in Ozempic label
The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a statement on Thursday.
Danish Regulators Flag Eye Risk for Novo’s Ozempic, Requesting EU Review
The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until now have declined to move forward with a more formal review. Two new studies have strengthened the link.
Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update
The decision was based on findings of the FLOW trial, which assessed the risk reduction from Ozempic therapy, a once-weekly subcutaneous semaglutide, in chronic kidney disease-related events. The randomized,
Europe allows Novo to include reduction of kidney disease in Ozempic label
The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a statement on Thursday.
Novo Nordisk’s Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes.
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision was based on findings of a trial,
Novo Nordisk gets EMA nod for potential update of Ozempic label
Novo Nordisk (NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for an update of the Ozempic label to reflect data from the FLOW kidney outcomes trial.
GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
Danish agency seeks probe as Ozempic study shows link to vision loss
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
PharmTech18h
Several Orphan Drugs Among Medicines Recommended for Approval by EMA in December
EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.
Neurizon Secures EU Orphan Status for ALS Drug
Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
DA: Former Pennsylvania doctor illegally filled prescriptions for 80 patients
A former Pennsylvania doctor was allegedly prescribing drugs illegally to dozens of patients out of his basement, according ...
Ozempic Blinding-Link Potential Prompts Regulator to Seek Probe
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
GSK announces EMA granted PRIME Designation for GSK5764227
GSK (GSK) announced that the European Medicines Agency, EMA, has granted Priority Medicines, PRIME, Designation for GSK5764227, its ...
devdiscourse16h
Potential Eye Risks Linked to Popular Diabetes Drug Ozempic in Recent Danish Studies
Danish studies have found a potential link between the diabetes drug Ozempic and a rare eye condition called non-arteritic ...
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...
GSK's Cancer Drug Jemperli Nears EU Marketing Expansion -- 2nd Update
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
FiercePharma3d
EMA backs Merck's Welireg, Bayer's ATTR med and Gilead's liver drug from $4.3B deal
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...